The Wnt signal pathways have key roles in embryonic development. Defects in the pathway have also been implicated in cancer of the colon and other organs 1, 2 . Two Wnt pathways have been identified: the canonical and noncanonical pathways. Activation of the canonical pathway induces transcription of a new set of genes through the β-catenin-T cell factor (TCF) complex, which regulates cell proliferation and differentiation 1 . Activation of the noncanonical pathway does not require β-catenin signaling and controls cell movement during morphogenesis 2 .
In the absence of Wnt ligands bound to their receptors, the cytoplasmic complex of APC and Axin provide a scaffold for GSK3β to phosphorylate β-catenin (Fig. 1a) . Phosphorylated β-catenin is then rapidly degraded through the ubiquitin pathway. When Wnt ligands bind to the cell-surface receptor Frizzled (Fzd), they trigger the phosphorylation of a cytoplasmic effector, Dishevelled (Dsh), which then inhibits the activity of GSK3β on the APC-Axin complex. Unphosphorylated, and therefore stable, β-catenin can then accumulate in the cytoplasm and form a complex with TCF in the nucleus, which initiates transcription of Wnt target genes (Fig. 1b) .
Canonical Wnt signaling in cancer
Most colon cancers and other digestive cancers are associated with mutations in APC, AXIN1 or CTNNB1, and ∼90% of colon cancers are associated with defects in the canonical Wnt signaling pathway (Fig. 1c) 1 . Mutant APC and Axin are unable to assist GSK3β in phosphorylating β-catenin. Similarly, mutations that lead to amino acid substitutions in the phosphorylated residues of β-catenin stabilize the protein.
Either type of disruption causes constitutive signaling independent of the upstream signal from Wnt.
On page 417-422, Hiromu Suzuki and colleagues add a new twist to this simplistic view on the canonical Wnt pathway 3 . In an earlier paper, they isolated genes that were preferentially hypermethylated in human colon and gastric cancers 4 . Among them, they identified a family of secreted Fzdrelated proteins (SFRPs) that can compete with Fzd for the Wnt ligands. Now, the authors report on experiments in which they expressed SFRPs in colon cancer cell lines carrying mutations in CTNNB1 or APC. SFRP1, SFRP2 and SFRP5 suppressed Wntdependent transcription by ∼60% (Fig. 1d) 
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cells. In contrast, MEFs that lacked Wip1, p19 and p16 were fully oncogenic when the oncogenes Hras or Myc were introduced. MEFs that lacked only Wip1 and p16 had an intermediate phenotype, as they were fully oncogenic when transformed by certain combinations of oncogenes, but not by others. The conclusion was that loss of Wip1 activates two tumor suppressor pathways, p19 and p16, both of which contribute to the resistance to transformation of cells lacking Wip1.
Living proof
Encouraged by the in vitro data, Bulavin et al. 3 went on to ask if ablation of Ppm1d would inhibit oncogenesis in vivo. The authors decided to study breast cancer development, as Wip1-null mice have a strong induction of p16 in the normal mammary epithelium, and previous work indicated that the presence of cyclin D1 (whose action is inhibited by p16) is required for induction of breast cancer by certain oncogenes 13 . The authors crossed mice deficient for Wip1 with three different strains of mice, each engineered to overexpress a different oncogene in the epithelium of the mammary gland. Bulavin et al. 3 found that mammary tumorigenesis in mice that expressed the Wnt1 oncogene in the mammary gland was not affected by the absence of Wip1, whereas mice that expressed either Hras or Erbb2 in the breast epithelium were relatively resistant to the development of breast cancer in the absence of Wip1. Finally, the authors show that when treated with a specific p38 MAPK inhibitor, tumor-resistant Wip1-null mice that express Erbb2 in the breast repressed expression of p16 and developed breast tumors. Together, these data indicate that the absence of Wip1 prevents breast cancer induction through constitutive activation of p38 MAPK, which in turn causes upregulation of the tumor suppressor p16 (Fig. 1 ).
Wip1 as a drug target
The present study indicates that inhibition of the Wip1 phosphatase could suppress the proliferation of certain types of cancer, most notably breast cancer. Phosphatases are, in principle, susceptible to targeting by drugs, as potent inhibitors of other phosphatases have been developed. The side effects of inhibition of Wip1 may also be acceptable, as Wip1-null mice develop normally, even though defects in immune function have been noted 12 . Not all types of cancer respond to antiproliferative signaling through the p16 or p19 tumor-suppressor pathways. Indeed, Bulavin et al. 3 show that breast cancers caused by the Wnt1 oncogene in mice are not inhibited by loss of Wip1. But a substantial fraction of breast cancers have increased expression of cyclin D1, and such tumors may benefit from Wip1 inhibition 14 .
greater and was suppressed by cotransfection with constructs expressing SFRPs. Furthermore, Wnt-dependent transcription was 3.5 and 7 times greater when the authors coexpressed wild-type or stable mutant β-catenin, respectively, in these cells.
The results establish that Wnt signal activation by mutant β-catenin or APC can be partially suppressed by upstream ligand competitors, and that Wnt signaling can be boosted further in a β-catenin-or APCmutant cell line by upstream Wnt ligands or by additional expression of β-catenin (Fig. 1d  and c, respectively) . Accordingly, it may be possible to suppress the tumor phenotype in Wnt-activated cancer cells by inhibiting the Fzd receptor through competition with antagonists. In fact, Hiromu Suzuki and colleagues show that colon cancer cells that overexpress SFRPs have less colony formation and a higher rate of apoptosis.
How much Wnt is required for tumorigenesis?
The authors suggest that β-catenin mutated at Ser45 in the HCT116 cells only partially stabilizes the protein, because phosphorylation may take place at three other residues, consistent with a recent report 5 . But phosphorylation at Ser45 seems to be essential for phosphorylation of the other residues 6, 7 . In this regard, it would be helpful to determine if deleting the remaining wild-type allele 8 , or all four phosphorylated residues 9 , would have a substantial effect.
Looking at the bigger picture of the Wnt signaling system, we must consider what might be allowing this dynamic signal regulation. Expression of exogenously introduced wild-type and Ser45-mutant β-catenin increased Wnt signaling in HCT116. Thus, Wnt signal-dependent transcription is not saturated in cells that carry the Ser45 mutation in only one of the alleles 10 . The increased Wnt signaling by expression of extra ligand can also be explained by Dsh-dependent inhibition of GSK3β phosphorylation of wild-type β-catenin synthesized from the other allele. Regarding SW480 cells with biallelic APC mutations 11 , additional signal from Wnt ligands may be explained by the flexible nature of the APC-Axin complex. For example, overexpression of Axin can compensate for the lack of APC in phosphorylating β-catenin 12 . Dsh inhibits GSK3β phosphorylation of β-catenin on the APC-Axin scaffold, but its mode of inhibition is not fully understood. Slowly, the pieces of the Wnt signaling puzzle are coming together and suggest that signaling can be regulated at many levels in a quantitative manner, with a wide, dynamic range.
Approximately 90% of primary colon cancer tissues showed methylation of SFRP1, whereas only ∼70% had APC mutations. Notably, methylation of SFRP1, SFRP2 and SFRP5 was also found in ∼90% of early colonic adenomas. Accordingly, silencing SFRP genes may be one of the earliest events in tumorigenesis. The new results suggest that we may be able to suppress Wnt signaling in cancer even when APC or CTNNB1 is mutated. LRP, co-receptor, low-density-lipoprotein receptor-related protein family 13 . Familial combined hyperlipidemia (FCHL), the most common inherited disorder of abnormal blood lipid levels, is believed to share part of its etiology with the metabolic syndrome 1 . The extent of this overlap has been difficult to define because of important differences in diagnosis. FCHL is typically diagnosed through an index individual affected with marked hyperlipidemia (elevated blood cholesterol or triglyceride levels) and normally excludes individuals with hyperlipidemia secondary to other coronary heart disease (CHD) risk factors, such as central obesity and maturity-onset diabetes (type 2 diabetes). More fundamentally, a diagnosis of FCHL demands that index individuals have a blood relative with primary hyperlipidemia, whereas the metabolic syndrome does not. On page 371-376 of this issue, Päivi Pajukanta and colleagues 2 present evidence that a specific haplotype of the gene encoding upstream transcription factor 1 (USF1) located in the chromosome 1q21-23 region, is associated with FCHL. They propose that USF1 is a good candidate for conferring susceptibility to the core features of the metabolic syndrome: insulin resistance, glucose intolerance, type 2 diabetes, central obesity, dyslipidemia (elevated blood triglyceride or low high density lipoprotein-cholesterol) and hypertension 2 .
Homing in on USF1
Pajukanta et al. 3 previously found evidence for linkage of the chromosome 1q21-23 interval to FCHL in a cohort of 31 Finnish families, identified through an index individual with early-onset CHD and blood cholesterol or triglyceride levels greater than or equal to ageand sex-specific 90 th percentiles. Subsequent studies supported these data and implicated the same chromosomal region in the etiology of type 2 diabetes [4] [5] [6] . In the present study, Pajukanta et al. 2 built on their previous work by systematically examining a stretch of DNA containing about 10 Mb for a genetic lesion conferring susceptibility to FCHL 2 . This involved tracking the transmission of 56 functionally unbiased singlenucleotide polymorphisms (SNPs) to the affected family members of 42 pedigrees with FCHL, including the 31 families who participated in the original linkage study. They examined six SNPs that had some association with FCHL in an additional 18 extended families. The two SNPs that produced the best evidence for association with FCHL are both located in the gene encoding USF1, a transcriptional activator that regulates a number of genes involved in whole-body lipid and glucose homeostasis 7, 8 . This report prompts two important questions. First, how compelling is the genetic evidence for the involvement of USF1 in FCHL and, by implication, the etiology of the condition? Second, irrespective of the contribution of USF1 to FCHL, do specific USF1 haplotypes increase the risk of type 2 diabetes or the metabolic syndrome?
Regarding the first issue, in the absence of existing linkage data, some investigators 9 argue for a statistical criterion of P < 5 × 10 -9 , whereas others emphasize the importance of replicating results in independent data sets and of biological plausibility 10 . In the present FCHL study, the alleles at the two associating loci (usf1s1 (exon 11) and usf1s2 (intron 7)) are in strong linkage disequilibrium and, based on family data, have major allele frequencies of about 0.65 in the Finnish population. The lowest P value (9 × 10 -7 ) was obtained for the triglyceride trait in men using the gametecompetition test, which views the transmission of alleles or haplotypes to affected individuals as a contest. These data were supported by the results of a second test statistic (HBAT-o) that determined which specific haplotypes were preferentially transmitted. The haplotype containing the minor alleles at the usf1s1 and usfs2 loci was transmitted less frequently to affected males with the triglyceride trait (P = 4 × 10 -3 ), prompting the authors to suggest that this might protect against FCHL in their families.
The HBAT-o test also produced evidence (P = 7 × 10 -4 ) for preferential transmission of the common USF1 haplotype to males with the triglyceride trait of FCHL, supporting the results from three different analyses: the gamete-competition test; a multilocus geno-PDT and a haplotype-based haplotype relative risk test. But even robust statistical data from a single cohort of families are not always replicated in another population. Because the Finnish families were, necessarily, selected on the basis of a complex phenotype and did not exclude individuals with type 2 diabetes, the size of the effect of the putative USF1 risk haplotype on any single FCHL-related trait is uncertain. Given the relatively high frequency of the risk haplotype, this effect will presumably vary according to an individual's susceptibility to develop FCHL, which we now know is attributable to at least four other genes 11 .
A SNP in an internal promoter
The evidence for association of USF1 with FCHL prompted Pajukanta et al. 2 to sequence this gene in 31 FCHL probands 2 . They found no amino acid changes in USF1 that could account for association of the putative USF1 risk haplotype with FCHL. Nor could they find any difference in USF1 mRNA levels in fat biopsy samples from individuals with FCHL with the risk haplotype versus those without. They did, however, identify a 
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The ubiquitous USF proteins regulate the transcription of many genes involved in lipid and glucose homeostasis. A new study provides genetic evidence that USF1 may confer susceptibility to high blood lipid levels.
